Assignee
MORPHOSYS AG
DE·58 granted patents·58 pending applications·1,770 citations·filing 1995–2025
Top patents by PatentIndex Score
116 records- 0197US6300064B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 1998·Granted Oct 9, 2001·794 cites·25 claims
- 0295US6706484B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Mar 16, 2004·158 cites·35 claims
- 0394US9758590B2Anti-CD38 human antibodies and uses thereofMORPHOSYS AG·Filed 2015·Granted Sep 12, 2017·15 cites·3 claims
- 0494US6753136B2Methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bondsMORPHOSYS AG·Filed 2001·Granted Jun 22, 2004·72 cites·19 claims
- 0594US6696248B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Feb 24, 2004·112 cites·74 claims
- 0693US7264963B1Protein(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Sep 4, 2007·104 cites·13 claims
- 0793US6294353B1Targeted hetero-association of recombinant proteins to multi-functional complexesMORPHOSYS AG·Filed 1995·Granted Sep 25, 2001·175 cites·29 claims
- 0892US7867495B2Anti-GM-CSF antibodies and uses thereforMORPHOSYS AG·Filed 2006·Granted Jan 11, 2011·25 cites·54 claims
- 0991US6653068B2Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTsMORPHOSYS AG·Filed 2001·Granted Nov 25, 2003·95 cites·32 claims
- 1090US9193799B2Fully human therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2013·Granted Nov 24, 2015·10 cites·40 claims
- 1188US2024309109A1Generation and profiling of fully human therapeutic antibodies specific for human cd38MORPHOSYS AG·Filed 2024·Application pending·0 cites
- 1287US11702463B2Canine antibody librariesMORPHOSYS AG·Filed 2021·Granted Jul 18, 2023·1 cites·20 claims
- 1387US9289490B2Combinations and uses thereofMORPHOSYS AG·Filed 2014·Granted Mar 22, 2016·10 cites·20 claims
- 1487US6828422B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Dec 7, 2004·95 cites·59 claims
- 1586US11059902B2Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2018·Granted Jul 13, 2021·1 cites·7 claims
- 1686US10259869B2Antibodies for IL-17CMORPHOSYS AG·Filed 2018·Granted Apr 16, 2019·6 cites·11 claims
- 1786US10184005B2Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2015·Granted Jan 22, 2019·4 cites·24 claims
- 1885US11224654B2Combinations and uses thereofMORPHOSYS AG·Filed 2016·Granted Jan 18, 2022·2 cites·18 claims
- 1985US11014978B2Canine antibody librariesMORPHOSYS AG·Filed 2018·Granted May 25, 2021·2 cites·17 claims
- 2083US10633439B2Antibodies for IL-17CMORPHOSYS AG·Filed 2019·Granted Apr 28, 2020·2 cites·18 claims
- 2183US9486547B2Radiolabelled antibody and uses thereofMORPHOSYS AG·Filed 2013·Granted Nov 8, 2016·6 cites·16 claims
- 2283US7049135B2Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complexMORPHOSYS AG·Filed 2003·Granted May 23, 2006·15 cites·26 claims
- 2383US2025074978A1Antibodies for il-17cMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 2482US11254734B2Fab molecules with a rodent hinge region and a non-rodent CH1 regionMORPHOSYS AG·Filed 2017·Granted Feb 22, 2022·2 cites·7 claims
- 2582US6692935B1Targeted hetero-association of recombinant proteins to multi-functional complexesMORPHOSYS AG·Filed 2000·Granted Feb 17, 2004·16 cites·26 claims
- 2681US10617691B2Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2016·Granted Apr 14, 2020·3 cites·16 claims
- 2781US2024392034A1Clinical assessment of m-protein response in multiple myelomaMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 2880US11987621B2Antibodies for IL-17CMORPHOSYS AG·Filed 2020·Granted May 21, 2024·1 cites·17 claims
- 2980US6667150B1Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complexMORPHOSYS AG·Filed 2000·Granted Dec 23, 2003·23 cites·36 claims
- 3079US11939395B2Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2021·Granted Mar 26, 2024·0 cites·6 claims
- 3179US9541559B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Jan 10, 2017·2 cites·32 claims
- 3278US9765152B2Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomibMORPHOSYS AG·Filed 2016·Granted Sep 19, 2017·2 cites·14 claims
- 3377US12018072B2Antibodies specific for human complement C5A receptor (C5AR)MORPHOSYS AG·Filed 2023·Granted Jun 25, 2024·0 cites·30 claims
- 3477US9579378B2Combinations and uses thereofMORPHOSYS AG·Filed 2013·Granted Feb 28, 2017·4 cites·16 claims
- 3577US8367586B2Collection and methods for its useMORPHOSYS AG·Filed 2011·Granted Feb 5, 2013·2 cites·30 claims
- 3677US2024417455A1Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 3776US10913792B2Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2018·Granted Feb 9, 2021·1 cites·7 claims
- 3876US10774154B2Complex-specific antibodies and antibody fragments and its useMORPHOSYS AG·Filed 2017·Granted Sep 15, 2020·1 cites·6 claims
- 3976US10655125B2Polypeptide libraryMORPHOSYS AG·Filed 2017·Granted May 19, 2020·1 cites·16 claims
- 4076US2023203189A1Clinical assessment of m-protein response in multiple myelomaMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 4175US9624293B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Apr 18, 2017·1 cites·14 claims
- 4275US7785859B2Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bondsMORPHOSYS AG·Filed 2003·Granted Aug 31, 2010·4 cites·32 claims
- 4374US10308722B2Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomideMORPHOSYS AG·Filed 2017·Granted Jun 4, 2019·1 cites·20 claims
- 4474US2024009196A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 4574US2024400657A1Antibodies targeting c5arMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 4672US11542329B2Antibodies targeting Glycoprotein VIMORPHOSYS AG·Filed 2019·Granted Jan 3, 2023·1 cites·18 claims
- 4771US2021347879A1Anti-gm-csf antibodiesMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 4871US2022283166A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 4970US11028165B2Nucleic acid encoding anti-GM-CSF antibodiesMORPHOSYS AG·Filed 2019·Granted Jun 8, 2021·0 cites·14 claims
- 5070US10533057B2Treatment for multiple myeloma (MM)MORPHOSYS AG·Filed 2016·Granted Jan 14, 2020·1 cites·5 claims
Showing the top 50 of 116 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →